Refractory epilepsy: a progressive, intractable but preventable condition?

被引:122
作者
Kwan, P
Brodie, MJ [1 ]
机构
[1] Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland
[2] United Christian Hosp, Dept Med & Geriatr, Div Neurol, Kwun Tong, Hong Kong, Peoples R China
来源
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | 2002年 / 11卷 / 02期
关键词
refractory epilepsy; seizures; prevention; antiepileptic drugs; epilepsy surgery; drug resistance;
D O I
10.1053/seiz.2002.0593
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Intractable seizures are just one manifestation of 'refractory epilepsy', which can be recognized as a distinct condition with multifaceted dimensions, including neurobiochemical plastic changes, cognitive decline and psychosocial dysfunction, leading to dependent behaviour and a restricted lifestyle. The biological basis of 'refractoriness' is likely to be multifactorial, and may include the severity of the syndrome and/or underlying neuropathology, abnormal reorganization of neuronal circuitry, alteration in neurotransmitter receptors, ion channelopathies, reactive autoimmunity, and impaired antiepileptic drug (AED) penetration to the seizure focus. Some of these deleterious changes may be a consequence of recurrent seizures. We hypothesize that 'refractory epilepsy' may be prevented by interrupting this self-perpetuating progression. There is increasing evidence that these patients can be identified early in the clinical course and, thus, be targeted early for effective therapeutic intervention. Failure of two first-line AEDs due to lack of efficacy or poor tolerability should prompt consideration of epilepsy surgery in a patient with a resectable brain abnormality. For the majority not suitable for 'curative' surgery, AEDs should be combined with the aim of achieving 'synergism'. This strategy has the potential to improve outcome by preventing the insidious progression to intractable 'refractoriness' and a downward spiralling quality of life. (C) 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 98 条
[1]  
[Anonymous], 1991, Lancet, V337, P1175
[2]  
Babb T L, 1999, Adv Neurol, V79, P763
[3]   Cryptogenic partial epilepsies with Anti-GM1 antibodies: A new form of immune-mediated epilepsy? [J].
Bartolomei, F ;
Boucraut, J ;
Barrie, M ;
Kok, J ;
Dravet, C ;
Viallat, D ;
Bernard, D ;
Gastaut, JL .
EPILEPSIA, 1996, 37 (10) :922-926
[4]   First genetic evidence of GABAA receptor dysfunction in epilepsy:: a mutation in the γ2-subunit gene [J].
Baulac, S ;
Huberfeld, G ;
Gourfinkel-An, I ;
Mitropoulou, G ;
Beranger, A ;
Prud'homme, JF ;
Baulac, M ;
Brice, A ;
Bruzzone, R ;
LeGuern, E .
NATURE GENETICS, 2001, 28 (01) :46-48
[5]  
Bausch S B, 1999, Curr Opin Neurol, V12, P203, DOI 10.1097/00019052-199904000-00012
[6]   Apoptosis and proliferation of dentate gyrus neurons after single and intermittent limbic seizures [J].
Bengzon, J ;
Kokaia, Z ;
Elmer, E ;
Nanobashvili, A ;
Kokaia, M ;
Lindvall, O .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (19) :10432-10437
[7]  
BENTAR MG, 1999, Q J MED, V92, P133
[8]   Do seizures beget seizures? An assessment of the clinical evidence in humans [J].
Berg, AT ;
Shinnar, S .
JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 1997, 14 (02) :102-110
[9]   A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy [J].
Bill, PA ;
Vigonius, U ;
Pohlmann, H ;
Guerreiro, CAM ;
Kochen, S ;
Saffer, D ;
Moore, A .
EPILEPSY RESEARCH, 1997, 27 (03) :195-204
[10]   Molecular neuropathology of human mesial temporal lobe epilepsy [J].
Blümcke, I ;
Beck, H ;
Lie, AA ;
Wiestler, OD .
EPILEPSY RESEARCH, 1999, 36 (2-3) :205-223